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ABSTRACT: The objectives of this study were to
evaluate the risk of neuropathy in patients with Parkin-
son’s disease (PD) and to evaluate the role of levodopa
exposure as a potential risk factor. A multicenter study of
330 patients with PD and 137 healthy controls with a
comparable age distribution was performed. With respect
to levodopa exposure, 144 patients had long exposure
(3 years) to levodopa (LELD), 103 patients had short
exposure (<3 years) to levodopa (SELD), and 83 patients
had no exposure to levodopa (NOLD). Nerve function was
evaluated using the reduced total neuropathy score. Right
sural sensory antidromic and peroneal motor nerve con-
duction studies were performed by neurophysiologists
who were blinded to the existence of neuropathy clinical
features or PD treatment. Overall, 19.40% of patients in
the LELD group, 6.80% in the SELD group, 4.82% in the
NOLD group, and 8.76% in the control group were diag-
nosed with neuropathy (axonal, predominantly sensory).
Multivariate logistic analysis indicated that the risk of neu-
ropathy was not influenced by disease duration, severity,
or sex. The risk of neuropathy increased by approximately
8% for each year of age (P<0.001; odds ratio [OR], 1.08;
95% confidence interval [CI], 1.037-1.128). The risk of
neuropathy was 2.38 higher in the LELD group than in the
control group (P50.022; OR, 2.38; 95% CI, 1.130-5.014).
In a comparison between patients with and without neu-
ropathy (Student’s t test), the levodopa dose was higher
(P< 0.0001), serum vitamin B12 levels were lower
(P5 0.0102), and homocysteine levels were higher
(P< 0.001) in the patients with neuropathy. Our results
demonstrate that the duration of exposure to levodopa,
along with age, is the main risk factor for the develop-
ment of neuropathy. Screening for homocysteine and vita-
min B12 levels and clinical-neurophysiological monitoring
for neuropathy may be advisable in patients with PD who
are receiving treatment with levodopa. VC 2013 Interna-
tional Parkinson and Movement Disorder Society
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Parkinson’s disease (PD) is a common neurodegener-
ative disorder that can cause significant disability and
decreases quality of life. The cardinal physical signs of
the disease are distal resting tremor, rigidity, bradyki-
nesia, and asymmetric onset. However, mostly in the
later stages of the disease, postural instability, muscu-
lar cramps, and numbness—more prominent in feet
and distal legs—also can occur. These latter symptoms
also are distinctive of a distal, predominantly sensory
neuropathy. This overlap between different clinical
entities may explain why for many years neurologists
might have overlooked the concurrence of peripheral
involvement as a possible additional cause of motor
performance and quality-of-life worsening in patients
with PD. Only in recent years have some studies sys-
tematically assessed the presence of neuropathy in PD
populations,1–3 suggesting that patients with idio-
pathic PD frequently may present clinical and/or neu-
rophysiological features of polyneuropathy.
However, some important questions remain open. In
particular, mainly due to some methodological limita-
tions, like studies that analyzed only case series,1
single-center studies,2,3 and studies that lacked or
included only small groups of patients with PD who
had no levodopa (L-dopa) exposure in the study
design,1–3 previous studies were unable to reach a
definitive conclusion on the causes responsible for the
neuropathy. To ascertain the risk factors for neuropa-
thy in idiopathic PD, and particularly whether L-dopa
plays a crucial, causative role, we carried out a multi-
center clinical/neurophysiological study in a large sam-
ple of patients with PD and age-matched controls,
stratifying our PD population on the basis of the dura-
tion of L-dopa exposure.
Patients and Methods
Between January and November 2011, we con-
ducted a cross-sectional study involving six Italian ter-
tiary referral centers for PD (Cagliari, Genoa, Naples,
Pisa, Turin, and Viareggio) by enrolling consecutive
patients who met inclusion criteria for the study. This
study received approval from the ethical committees
of each center. A written informed consent form was
obtained from each patient.
Patients
All patients fulfilled United Kingdom Brain Bank cri-
teria for the clinical diagnosis of PD, and the diagnosis
was determined by movement disorders specialists. We
excluded patients from this study who had a history
of other systemic illnesses, such as chronic infectious
diseases, diabetes, or other metabolic, endocrine, or
autoimmune illnesses; cancer; chronic alcohol con-
sumption; toxic exposure, and any family history of
neuropathy. The daily dose and duration of L-dopa
and dopamine agonists were determined for each
patient by a retrospective chart review. We defined the
daily L-dopa dose as the average daily dosage of L-
dopa in the last 6 months. With respect to L-dopa
exposure, patients were subdivided into those with
exposure for more than three years (long exposure to
L-dopa [LELD]), exposure for less than three years
(short exposure to L-dopa [SELD]), or no exposure
(no L-dopa [NOLD]). The criterion for defining SELD
as a period no longer than three years was arbitrary;
however, it was driven by the fact that, after three or
four years of L-dopa, up to 50% of PD patients can
develop dyskinesias and motor fluctuations4; this effect
is the clinical reflection of a breakdown of a neuronal
homeostasis in the central nervous system. Moreover,
although the objective of our research was to explore
the peripheral nervous system, we decided to tighten
the window of L-dopa exposure to this period. Assess-
ment using the motor subscale (part III) from the Uni-
fied Parkinson’s Disease Rating Scale (UPDRS III) and
a complete neurological examination were carried out
in all patients. No patients were taking any vitamin
supplementation.
Controls were mainly recruited from the familial/
social network of the patients and had no history of
neurodegenerative disease or other illness that puta-
tively affects peripheral nerves. Age distribution for
the control group was comparable to that for the PD
group.
Procedures
Nerve function was evaluated using a sensitive, vali-
dated neuropathy composite score, the reduced version
of the total neuropathy score (TNSr), which is the ver-
sion previously validated by Cornblath et al5 and
modified by Cavaletti et al6 (ie, evaluation of sensory
symptoms, pin sensibility, vibration sensibility,
strength, and deep tendon reflex, without the quantita-
tive determination of vibration threshold but with the
neurophysiological investigation of sensory sural and
motor peroneal peripheral nerves). For each patient
and control participant, a detailed neurological history
(with particular reference to the presence of signs of
peripheral nerve damage) was drawn up.
As required for TNS design, the presence of sensory,
motor, or autonomic symptoms was first assessed by
interviewing the patients. The neurological examina-
tion was based on the standard evaluation of strength,
deep tendon reflexes, and examination of pin sensibil-
ity using a sterile disposable needle; and disturbance
of vibration sensibility was demonstrated by decreased
perception of the 128-Hz diapason vibration, as
described by Cavaletti et al.6
Nerve conduction studies were performed using
standard laboratory techniques. Right sural sensory
antidromic and peroneal motor nerve conduction was
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studied using standardized techniques and fixed dis-
tances. The temperature was maintained at >32C. To
avoid any bias, the clinical neurophysiologist was
blinded to the participant’s condition (ie, exposure to
L-dopa or drug dosages of PD patients, existence of
clinical features of neuropathy).
To calculate the TNSr, the amplitude of the anti-
dromic sensory potential in one sural nerve and the
compound muscle action potential (CMAP) in the ipsi-
lateral common peroneal nerve were used. The neuro-
physiological normal reference values necessary for
TNS calculation were previously determined in each
neurological department in age-matched individuals.
According to the results from the clinical and neuro-
physiological examinations, the TNSr score was calcu-
lated as previously described.5 For each item, the
possible score ranged from 0 (normal) to 4 (worst pos-
sible results), so that the score ranged from 0 to 28.
According to previously published criteria,7 only
patients who presented a combination of neuropathic
symptoms or signs with at least an abnormal parame-
ter in one of the explored nerves were considered as
patients with neuropathy. We determined serum vita-
min B12 and homocysteine (Hcy) levels for all patients
involved in the study. Fasting blood tests were carried
out 12 hours after the last dose of L-dopa. For those
with neuropathy, we performed further blood investi-
gations, including complete blood count, urea, creati-
nine, liver enzymes, liver function tests, glucose and
hemoglobin A1C (HbA1C), electrolytes, thyroid func-
tion (free tri-iodothyronine, free tetraiodothyronine,
thyroid-stimulating hormone), erythrocyte sedimenta-
tion rate, polymerase chain reaction, antinuclear anti-
body, extracted nuclear antibody testing, rheumatoid
factor, and serum protein electrophoresis.
Statistical Analysis
An initial multivariate logistic analysis was used to
demonstrate the possible effects on neuropathy occur-
rence of L-dopa exposure, age, sex, disease duration,
disease severity, and blood levels of vitamin B12 and
Hcy. The analysis was carried out considering neurop-
athy as a dependent variable and considering duration
of L-dopa exposure, global UPDRS III score (categori-
cal variable), sex, age (continuous variable), and their
second-order interactions as independent variables.
Disease duration and levels of vitamin B12 and Hcy
(independent continuous variables) were considered
without interactions.
On the basis of the results, a second logistic analysis
was performed that included only patients with PD to
demonstrate the possible independent effects of age on
neuropathy (considered as a confounding variable)
and L-dopa exposure (LELD vs SELD and NOLD). A
multivariate logistic analysis was performed using a
backward stepwise procedure based on eliminating the
least significant interaction and independent variables
at each step. The Student t test for the comparison of
two means was used to evaluate differences in serum
vitamin B12 and Hcy levels, TNSr score, sensory
action potential amplitude of the sural nerve, CMAP
amplitude of the peroneal nerve, and L-dopa daily
dose between patients with and without neuropathy.
The eventual difference in the pull test score
(UPDRS III, sub-item 30) between patients with and
without neuropathy was evaluated with the z test for
difference between two proportions. A P value<0.05
was considered significant. Data from the survey were
analyzed using the Statistical Package for the Social
Sciences (version 19; SPSS Inc., Chicago, IL, USA).
Results
Between January and November 2011, 472 partici-
pants (335 patients with PD and 137 age-matched con-
trols) were consecutively screened. Four patients were
subsequently excluded because hematological findings
disclosed previously unrecognized diabetes (high glu-
cose or HbA1C levels in three patients) or monoclonal
gammopathy (one patient); another patient was
excluded because as he was diagnosed with cancer after
the screening visit.
Of the patients with PD who were finally included,
144 patients (56 women) had L-dopa exposure longer
than 3 years (LELD; mean age, 69.1 years; mean illness
duration, 9.9 years; mean UPDRS III score, 24.1); 103
patients (38 women) had L-dopa exposure shorter than
3 years (SELD; mean age, 67.6 years; mean illness
duration, 3.8 years; mean UPDRS III score, 18.2); and
83 patients (34 women) had no exposure to L-dopa
(NOLD; mean age, 62.0 years; mean illness duration,
3.0 years; mean UPDRS III score, 15.7). There were
137 controls (70 women; mean age, 68.0 years).
Twenty-eight of 144 patients (19.40%) with LELD,
seven of 103 patients (6.80%) with SELD, four of 83
patients (4.82%) with NOLD, and 12 of 137 age-
matched controls (8.76%) were diagnosed with neu-
ropathy (see Tables 1 and 2). The TNSr score was sig-
nificantly higher in patients with neuropathy than in
those without neuropathy (difference in absolute
value, 9.8; P<0.0001; 95% confidence interval [CI],
8.9–10.7); the amplitude of the sensory potential of
the sural nerve (RV) was significantly lower in patients
with neuropathy than in those without neuropathy
(difference in absolute value, 9.0; P<0.0001; 95%
CI, 8.22-9.88). Also, the CMAP of the common pero-
neal nerve (mV) was significantly lower in patients
with neuropathy than in those without neuropathy
(difference in absolute value, 2.6; P<0.0001; 95%
CI, 1.96-3.14). The clinical and electrophysiological
features of the neuropathic patients were consistent
with an axonal, predominantly sensory neuropathy.
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The first multivariate logistic analysis demonstrated
that all interactions were not statistically significant;
therefore, they were eliminated from the model. More-
over, the analysis indicated that the risk of neuropathy
was not influenced by disease duration (P50.91; odds
ratio [OR], 1.01), disease severity assessed by the
UPDRS III total score (P5 0.20; OR, 1.02), sex
(P5 0.25; OR, 1.64), serum vitamin B12 level
(P5 0.26; OR, 0.99), or serum Hcy level (P50.59;
OR, 1.01). Consequently, these variables were elimi-
nated from the model. In the end, the risk of neuropa-
thy increased by 8% for each year of age (P<0.001;
OR, 1.08; 95% confidence interval [CI], 1.037-1.128).
Moreover, the risk of neuropathy was 2.38 higher in
individuals who had LELD than in healthy individuals
(P50.022; OR, 2.38; 95% CI, 1.130-5.014). The
logistic regression model (Table 3) clearly indicated
that age and LELD were independently associated
with neuropathy.
TABLE 1. Clinical and demographic characteristics of subgroups in the study population
Characteristic No. of patients Mean age, y
Mean duration
of illness, y
Mean UPDRS-III
score
LELD
Women, n5 56
Without neuropathy 46 67.4 9.8 24.3
With neuropathy 10 71.1 12.2 29.9
Men, n5 88
Without neuropathy 70 69.0 9.9 22.0
With neuropathy 18 72.9 8.7 28.2
SELD
Women, n5 38
Without neuropathy 37 66.6 3.4 19.6
With neuropathy 1 74.0 1.0 15.0
Men, n5 65
Without neuropathy 59 67.8 4.2 17.0
With neuropathy 6 69.7 3.9 20.0
NOLD
Women, n5 34
Without neuropathy 33 62.1 2.7 16.6
With neuropathy 1 70.0 1.0 8.0
Men, n5 49
Without neuropathy 46 61.2 3.2 14.7
With neuropathy 3 69.7 1.0 15.0
Controls
Women, n5 70
Without neuropathy 65 66.8
With neuropathy 5 73.6
Men, n5 67
Without neuropathy 60 67.9
With neuropathy 7 75.4
UPDRS-III, Unified Parkinson’s Disease Rating Scale, motor part; LELD, long exposure to L-dopa (>3 years); SELD, short exposure to L-dopa (3 years);
NOLD, no exposure to L-dopa.
TABLE 2. Prevalence of neuropathy in the four patient
groups
No. of patients
Variable
Without
neuropathy
With
neuropathy Total
Prevalence of
neuropathy, %
NOLD 79 4 83 4.82
LELD 116 28 144 19.40
SELD 96 7 103 6.80
Controls 125 12 137 8.76
Total 416 51 467 10.92
NOLD, no exposure to L-dopa; LELD, long exposure to L-dopa (>3 years);
SELD, short exposure to L-dopa (3 years).
TABLE 3. First multivariate logistic regression: Effect of
age and L-dopa exposure in patients (no exposure, short
exposure, and long exposure to L-dopa) versus controls
on neuropathy
Variable P OR 95% CI
Age (quantitative variable) 0.00028 1.08 1.037-1.128
NOLD vs controls 0.7255 0.81 0.243-2.678
SELD vs controls 0.5937 0.77 0.286-2.046
LELD vs controls 0.0225 2.38 1.130-5.014
OR, odds ratio; CI, confidence interval; NOLD, no exposure to L-dopa;
SELD, short exposure to L-dopa (3 years); LELD, long exposure to L-dopa
(>3 years).
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The second multivariate logistic analysis (Table 4)
unambiguously showed that age and LELD were inde-
pendently associated with neuropathy. Namely, the
risk of neuropathy increased by 7% for each year of
age (P5 0.0055; OR, 1.07; 95% CI, 1.02-1.12). The
risk of neuropathy was 3.083 higher in individuals
who had LELD than in individuals who had short
exposure and no exposure to L-dopa (P5 0.0035; OR,
3.08; 95% CI, 1.45-6.56).
The Student t test indicated that L-dopa dose distri-
bution was significantly higher in patients with neu-
ropathy than in those (LELD and SELD) without
neuropathy (difference in absolute value, 404.9;
P< 0.0001; 95% CI, 321.5–488.3) (Fig. 1).
The results showed that, among patients with PD
who were receiving L-dopa (LELD and SELD) and had
neuropathy, 22 of 35 had a pull test score 2 (UPDRS
III, sub-item 30); whereas, among those without neu-
ropathy, only 30 of 212 had a pull test score 2,
equal to 14%. This difference was significant (z test;
P< 0.0001).
Serum vitamin B12 levels were significantly lower in
patients with neuropathy than in those without
neuropathy (difference in absolute value, 58.3;
P5 0.0008; 95% CI, 24.1–92.4) (Fig. 2). Serum Hcy
levels were significantly higher in patients with neu-
ropathy than in those without neuropathy (difference
in absolute value, 4.2; P5 0.0001; 95% CI, 2.03–
6.36) (Fig. 3). As stated in the study protocol for the
patients with PD who had neuropathy, an additional,
extensive hematological investigation was performed,
and the results for all neuropathic patients were
within normal values.
Discussion
In recent years, some studies have reported an
increased prevalence of neuropathy in patients with
PD.1–3 However, those studies shared an important
limitation: they only included patients with PD who
were exposed to L-dopa. For this reason, although
they hypothesized that prolonged L-dopa use directly
or indirectly leads to neuropathy, they could not
exclude the possibility that other factors, including PD
“alone,” might cause peripheral impairment.8 With
this unanswered issue in mind, to ascertain whether L-
dopa plays a crucial causative role in neuropathy, we
choose to stratify our large PD population according
to the duration of L-dopa exposure. Moreover, a
group of L-dopa-naive PD patients also was studied
along with a group of healthy controls.
Our findings provide clear evidence that the dura-
tion of L-dopa exposure, but not disease duration or
disease severity, is strongly associated with the pres-
ence of neuropathy in patients with PD, thus support-
ing the role of L-dopa as a main risk factor. In
TABLE 4. Second multivariate logistic regression
(considering only patients with Parkinson’s disease): Effect
of age and long exposure to L-dopa versus short exposure
and no exposure to L-dopa
Variable P OR 95% CI
Age (quantitative variable) 0.0055 1.07 1.02-1.130
LELD vs SELD and NOLD 0.0035 3.08 1.45-6.56
OR, odds ratio; CI, confidence interval; LELD, long exposure to L-dopa (>3
years); SELD, short exposure to L-dopa (3 years); NOLD, no exposure to
L-dopa.
FIG. 1. The distribution of L-dopa (LD) doses (mg/day) in patients who
had Parkinson’s disease (PD) with and without neuropathy.
FIG. 2. The distribution of serum vitamin B12 levels in patients who
had Parkinson’s disease (PD) with and without neuropathy.
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addition, a positive relationship between the L-dopa
daily dose and the presence of neuropathy has been
suggested; that is, the longer the duration of L-dopa
treatment and, presumably, the higher the L-dopa
dose, the greater the risk of neuropathy.
The positive association of neuropathy with both
vitamin B12 deficiency and increased Hcy levels
observed in our study replicates on a larger scale the
data previously published.1–3,9,10 In particular, our
findings are confirmatory of the data originally
described by Rajabally and Martey, who reported for
the first time a positive relationship between neuropa-
thy and low vitamin B12 levels,3 as well as recent
data regarding a strong association between neuropa-
thy and increased Hcy levels.1,2
The increase in Hcy during oral L-dopa as well as
duodopa intestinal infusion11–14 are related to the con-
sumption of methyl groups by COMT; vitamin B12,
vitamin B6, and folate are needed cofactors for Hcy
metabolism. Vitamin B12 deficiency, which recently
was identified as a potential cause of reversible periph-
eral neuropathy in the elderly,15,16 reportedly is inver-
sely associated with L-dopa dose in patients who have
PD and neuropathy. In most cases, as observed in our
study, vitamin B12 levels were significantly lower than
those observed in healthy controls, yet they were not
always absolutely deficient. This suggests that the neu-
ropathic changes could be related to the exposure to
toxic metabolites (Hcy, methylmalonic acid [MMA])
resulting from a combination of high L-dopa concen-
tration and cobalamine functional insufficiency, rather
than vitamin B12 deficiency per se.
The increased L-dopa-related Hcy levels and their
direct association with the risk of neuropathy observed
in our cohort confirm the potential toxic effects of this
metabolite on peripheral nerves. Unfortunately, as a
limitation of our study, we could not assess the MMA
levels in our patients. Hcy can cause neurotoxicity
through several mechanisms, by increasing vulnerability
to mitochondrial toxins and rising free radicals, by
inducing inflammatory reactions, and also by impairing
DNA repair mechanisms.17–19 L-Dopa-associated,
increased Hcy levels reportedly were associated with
signs of sural axonal neurodegeneration in an electro-
physiological study of patients with PD and healthy
controls.20 The role of high levels of Hcy in inducing
peripheral nerve damage has been confirmed in diabetic
peripheral neuropathy,21 in patients with 5,10-methyle-
netetrahydrofolate reductase deficiency,22 and in a
recent longitudinal clinical and electrophysiological study
conducted on a large group of elderly individuals.23 The
evidence that only a proportion of PD patients on L-
dopa therapy develop neuropathy could be due to a
genetic susceptibility, for example involving methyltetra-
hydrofolate reductase, for which the potential risk might
be related to the possibility of having Hcy elevation with
L-dopa therapy.1
Because the inhibitors of catechol-O-methyltransferase
(COMT) can effectively reduce plasma Hcy levels,24 in
the present study, we did not plan to recruit patients on
stable therapy with COMT inhibitors; however, our
study’s next steps will include the assessment of the
putative protective role of COMT inhibition on the
development of neuropathy and the clinical and electro-
physiological follow-up of PD patients with neuropathy
after adequate supplementation therapy.
We decided to assess neuropathy by means of both
clinical and electrophysiological measures using a
blinded procedure; however, blinding is extremely dif-
ficult in this setting and, for obvious reasons, only
neurophysiologists, but not neurologists, were blinded
to the existence of clinical features of neuropathy or
disease treatment (exposure and time of exposure to L-
dopa or drug doses in patients with PD). In previous
reports, either investigators were not blinded with
regard to the patient’s condition1,2 or the unblinded
assessment was carried out only on a clinical basis.3
Because we were aware that the diagnosis of periph-
eral neuropathy based only on clinical grounds might
be difficult because of the wide overlapping of PD-
related symptoms and neuropathy-related complaints
(pain, paraesthesias, sensory symptoms, and impaired
balance), we defined patients and controls as neuro-
pathic when there was an abnormal electrophysiologi-
cal parameter in at least one of the explored nerves,
but the diagnosis had to be confirmed on clinical
grounds. In all neuropathic patients, we observed a
reduction of sural nerve amplitude, which was propor-
tionally more relevant than the common peroneal
CMAP reduction. Similarly, the impairment of the
FIG. 3. The distribution of homocysteine levels in patients who had
Parkinson’s disease (PD) with and without neuropathy.
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sensory item on the rTNS was greater than that of the
motor item (which was normal or only slightly abnor-
mal in the large majority of the neuropathic patients).
Taken together, the clinical and electrophysiological
features of the neuropathic patients were consistent
with a predominantly sensory neuropathy. On the
other hand, we are aware that the criteria chosen for
the diagnosis of neuropathy in the present study were
selective, and both asymptomatic and small fiber neu-
ropathies could have been under diagnosed (the for-
mer lacking the criteria for neuropathy-related
complaints, and the latter lacking the electrophysiolog-
ical criteria).
In summary, we observed a significantly greater
prevalence of neuropathy in patients with PD com-
pared with healthy controls, and there was a signifi-
cant relationship of time and, to a lesser extent, dose
exposure to L-dopa. To date, the clinical relevance of
sensory neuropathy in the context of PD motor disabil-
ity had not been previously assessed. Our findings of an
association between neuropathy and postural instability
might highlight the effect of peripheral involvement in
worsening PD motor impairment. Because the postural
imbalance due to neuropathy-related sensory disturban-
ces can be treated by specific rehabilitative protocols,
which may differ from those classically adopted for
PD, the early detection and management of neuropathy
in the course of PD might have great clinical relevance.
The positive association between neuropathy, low
serum vitamin B12 levels, and mainly high serum Hcy
levels could be related to L-dopa exposure (in terms of
duration and, presumably, daily amount) in predis-
posed individuals. Periodic Hcy, vitamin B12, and
folate screening, together with serial clinical and neu-
rophysiological assessment for neuropathy, may be
advisable in patients with PD who are receiving L-dopa
treatment. We cannot exclude the possibility that the
lack of other detoxificant factors, such as vitamin B6
either alone or in combination with vitamin B12 defi-
ciency, as recently described in two cases of PD with
axonal neuropathy in patients receiving duodopa treat-
ment,9 could play a role in altering peripheral nerve
homeostasis. However, the dietary supplementation of
vitamin B6 is not advisable in patients with PD because
of the potential interference with L-dopa metabolism.
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